Cepheid yesterday announced it has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert Ebola, a molecular diagnostic test for Ebola Zaire Virus that delivers results in less than two hours.
The test runs on the Cepheid GeneXpert Systems, the world’s leading molecular diagnostic platform with over 8,000 systems deployed globally in both developed and emerging market countries.
“Cepheid has historically played a leading role in developing molecular diagnostics as an aid to infection control efforts, and the current Ebola crisis represents an extreme example of the need for sensitive, fast, and easy to use diagnostics to aid in patient management and isolation requirements,” said John Bishop, Cepheid’s Chairman and CEO. “We believe this is a major step in strengthening the arsenal of tools being deployed to address the current situation.”
On August 5, 2014 the U.S. Secretary of Health and Human Services declared that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection of Ebola virus. Cepheid’s Xpert Ebola has not been FDA cleared or approved, but will remain available in the U.S. as an EUA product as long as the declared emergency remains in effect or it ceases to be authorized by FDA.
“With support from the Bill & Melinda Gates Foundation and the Paul G. Allen Family Foundation (provided via the National Philanthropic Trust Fund for Global Health and Development), Cepheid was able to leverage its extensive development experience to expedite delivery from the initial prototype to an emergency use only product in just 90 days,” said David Persing, MD, Ph.D., Cepheid’s Chief Medical and Technology Officer. “We expect that this technology will help to expedite the evaluation of suspected cases and to enable more effective field surveillance activities already underway in endemic areas.”
Xpert Ebola has been authorized by FDA under an Emergency Use Authorization for use by CLIA moderate and high complexity laboratories or similarly qualified non-U.S. laboratories. The test will begin shipping in April 2015.
Source: Cepheid press release, edited for Global Biodefense.
Editor Recommends: Diagnostic-Gear Maker Cepheid to Develop Rapid Test for Ebola Virus (WSJ)
